🧬 $25M Fund, 20 Companies, Zero Failures: A Biotech Investing Secret | Sergey Jakimov (3/4)
"If you die, all your crypto doesn't make sense. All your sustainability doesn't make sense. You have not solved the major existential issue or the major existential threat that you have."
In this episode of The Biotech Startups Podcast, host Jon Chee continues his conversation with Sergey Jakimov, Managing Partner at LongeVC, as he reveals launching a $25 million longevity fund. Leveraging relationships with top universities and a scientific advisory board featuring Nobel Prize winners, Sergey built a fund with an unconventional thesis: tackle age-related diseases one at a time, investing solely based on patient outcomes. The results—20 companies, zero write-offs in 3.5 years, with portfolio companies approaching unicorn status.
The conversation turns personal when Sergey shares his experience as a rare disease patient. At 28, a rare autoimmune neurodegenerative condition left him partially paralyzed, forcing him through a healthcare system offering only outdated treatments. This experience fundamentally reshaped his investment philosophy and cemented his belief that biotech is the most important industry. Sergey also discusses expanding his platform with Ani.vc and the Longevity Science Foundation, while reflecting on why health span and "joy span" matter more than simply extending lifespan.
-------- Â
35:33
--------
35:33
🧬 The Bank Heist Model: How to Build Your Startup Team | Sergey Jakimov (2/4)
"Building a deep tech company or building anything, pretty much, like being a founder in anything, it's like planning a bank robbery. It's like putting together a crew where, you know, you need a driver, you need someone to pick locks, you need someone to not sell, and you need someone who has the intellectual capacity to come up with a plan."
In this episode of The Biotech Startups Podcast, Sergey Jakimov, Managing Partner at LongeVC, shares his journey from uncertain graduate student in Budapest to serial deep tech founder. He discusses launching his first startup at age 22 in the conservative oil and gas industry with zero experience, pioneering drug-eluting coatings for orthopedic implants, and building Lungesys—a clinical data platform that revolutionized trial patient recruitment and helped establish the world's largest biobank.
Sergey challenges the "dropout culture" narrative while defending both formal education and learning by doing. He reveals why the least specialized person often makes the best founder and shares surprising truths about big pharma, including that only 14% of first-in-class cancer drugs are developed internally.
-------- Â
42:39
--------
42:39
🧬 Childhood Without Tech: Building a Foundation for VC Success | Sergey Jakimov (1/4)
"Retrospectively, this was honestly the best childhood one can get, and it was absolutely without gadgets."
In this episode of The Biotech Startups Podcast, we explore the formative years of Sergey Jakimov, founding partner at LongeVC, as he takes us from his childhood in post-Soviet Latvia to his graduate studies in Budapest. Sergey shares what it was like growing up in a small rural town near the Russian border, where limited resources, no technology, and long winters shaped his resilience, diplomacy, and drive to succeed.​
Sergey recounts his unlikely journey into competitive tennis under a retired national coach, training on concrete courts and turning the sport into both a discipline and a livelihood. He describes the grueling path to university admission—waking at 2 AM every Saturday for four-hour bus rides to attend prep courses in Riga—and the intense workload that followed, surviving on just three to four hours of sleep while juggling translation work and coaching gigs. A pivotal parliament internship shattered his idealistic views of government, leading him to embrace technocracy and meritocracy as guiding principles. Finally, Sergey reflects on earning his master's at Central European University in Budapest, where diverse perspectives and world-class academics further expanded his worldview and prepared him for entrepreneurship.​​
-------- Â
36:53
--------
36:53
🧬 How Autonomous Science Will Change Drug Discovery Forever | Jimmy Sastra (Part 4/4)
"Risk management is really just planning for when things go wrong."
In this final episode with Jimmy Sastra, PhD, co-founder and CEO of Monomer Bio, host Jon Chee explores how Jimmy redefines biotech leadership by treating fundraising as a strategic tool rather than a necessity. The conversation dives into building a company that combines scalable software with hands-on lab services, the importance of creativity and risk management in uncertain times, and Monomer’s bold vision for "autonomous science"—where AI and robotics revolutionize experimentation.
Alongside deep biotech insights, Jimmy shares personal reflections on balancing entrepreneurship, family, and his immigrant journey while pushing the boundaries of automation in life sciences.
-------- Â
25:58
--------
25:58
🧬 Autonomous Labs: The Future of Cell Culture | Jimmy Sastra (Part 3/4)
"People are looking at cells, making decisions, and then acting on them—that’s a robotics loop. I felt it could be done autonomously."
In this episode of The Biotech Startups Podcast, host Jon Chee sits down with Jimmy Sastra, co-founder and CEO of Monomer, to discuss how his team transformed hands-on lab automation consulting into a breakthrough biotech robotics company. Jimmy shares how Monomer’s vertically integrated platform unites robotics, software, and biology to automate cell culture, cut reliance on animal models, and boost reproducibility.
He also explains the company’s adaptive go-to-market strategy—ranging from software-only pilots to full robotic deployments—and reflects on the power of cross-disciplinary teamwork, global collaboration, and flexibility in navigating today’s challenging biotech landscape.
The Biotech Startups Podcast by Excedr features weekly conversations with founders, scientists, and investors driving biotech innovation. Host Jon Chee dives into the challenges of building biotech startups, from pre-seed to IPO. New episodes every Monday and Thursday.
Ireland